Tag: CBT > Preclinical Medical Cannabis Research

Cannabis Industry Research

Abstrax, Western Washington University Publish Preclinical Whitepaper on Cannabis Terpenes, Behavioral Responses

The preclinical research identifies biological sex as a key variable in terpene response, opening new directions for precision formulation.

April 29, 2026

Medical Cannabis Access and Pricing

Medical Cannabis at Inflection Point: Policy, Science, What Comes Next (Opinion)

From New York’s clinical leadership to emerging product standards, patient care is becoming the market’s north star.

February 10, 2026

Cannabis Industry Research

Gelteq Preclinical Results Show Increased Medicinal Cannabinoid Absorption

The science-based developer of gel-based oral delivery systems announced the positive absorption and bioavailability results for its proprietary platform.

January 13, 2026

Cannabis Industry Research

The Man Behind DEA’s Federal Marijuana Scam

DEA Senior Policy Adviser Matthew Strait defied presidential mandates for medical research, MMJ International Holdings claims.

January 28, 2025

Industry Headlines

Attorney General, DEA Director, Judge Under Federal Court Summons Over DEA Marijuana Policy

Despite the DEA’s policy, MMJ International is moving forward with the FDA on cannabis drug development for Huntington’s disease.

January 6, 2025

Industry Headlines

DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder

MMJ submitted an FDA Investigational New Drug application for a cannabis-derived medication.

December 11, 2024

Industry Headlines

FDA Clears MAPS Researchers to Proceed With Cannabis Study for Veterans With PTSD

The Multidisciplinary Association for Psychedelic Studies (MAPS) researchers negotiated with the FDA for three years.

November 22, 2024

Industry Headlines

‘Sleepy’ Cannabis: Study to Show Cannabinol (CBN) Increases Sleep

The non-hallucinogenic marijuana constituent increases sleep in rats.

November 12, 2024

Cannabis Industry Research

Medical Marijuana Act Signed by Biden Would Hinder Research Under Rescheduling

The Medical Marijuana and Cannabidiol Research Expansion Act’s requirements would remain under Schedule III, a congressional researcher says.

September 20, 2024

Industry Headlines

MMJ BioPharma Suing DEA Over Cannabis Reform, Medical Research

The biopharmaceutical company filed a lawsuit, citing ‘unjustified’ delays in processing an application for medical research.

September 11, 2024

Cannabis Industry Research

Raphael Pharmaceutical Issues Letter to Shareholders

The letter highlights the company’s exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis, recently commenced clinical study, broader pipeline opportunities, and overall mission and vision.

July 9, 2024

Cannabis Industry Research

Cannabis Company Sues DEA Over Application to Grow for Clinical Trials

Rhode Island-based MMJ BioPharma Cultivation Inc. is seeking an order to halt the DEA’s ‘unconstitutional actions’ as it awaits approval to grow cannabis.

April 8, 2024